Syneron Medical (Nasdaq: ELOS) reported earnings on May 22. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), Syneron Medical met expectations on revenues and met expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped slightly. Non-GAAP earnings per share expanded. GAAP loss per share was unchanged.

Margins grew across the board.

Revenue details
 Syneron Medical reported revenue of $61.2 million. The four analysts polled by S&P Capital IQ wanted to see sales of $61.2 million on the same basis. GAAP reported sales were the same as the prior-year quarter's.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at $0.02. The four earnings estimates compiled by S&P Capital IQ predicted $0.02 per share. Non-GAAP EPS were $0.02 for Q1 compared to -$0.05 per share for the prior-year quarter. GAAP EPS of -$0.07 were the same as the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 53.0%, 160 basis points better than the prior-year quarter. Operating margin was -4.2%, 60 basis points better than the prior-year quarter. Net margin was -4.0%, 20 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $74.9 million. On the bottom line, the average EPS estimate is $0.12.

Next year's average estimate for revenue is $289.9 million. The average EPS estimate is $0.47.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 700 members out of 732 rating the stock outperform, and 32 members rating it underperform. Among 176 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 171 give Syneron Medical a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Syneron Medical is buy, with an average price target of $16.50.

Is Syneron Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.